Investigation of 68Ga-Labeled Magnetic Ferrite Nanoparticles PET/MRI Dual-Modal Imaging Probe
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2022.0311
- VernacularTitle:68Ga标记的磁性铁氧体纳米颗粒PET/MRI双模态显像探针的制备及研究
- Author:
Wan-ru LI
1
;
Guang-feng CHEN
1
;
Ting YANG
1
;
Si-qi HU
1
;
Yuan YANG
1
;
Xiao-li MA
2
;
Yong ZHANG
1
Author Information
1. Department of Nuclear Medicine， The Third Affiliated Hospital of Sun Yat-sen University， Guangzhou 510630， China
2. Laboratory Animal Centre of South China Agricultural University， Guangzhou 510640， China
- Publication Type:Journal Article
- Keywords:
PET/MRI dual-modal imaging;
magnetic nanoparticles;
fibroblast activation protein inhibitor
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2022;43(3):430-436
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo prepare 68Ga-labeled magnetic ferrite nanoparticles PET/MRI dual-modal imaging probe and evaluate the possibility of using it as a novel molecular probe for prostate cancer imaging. MethodsUsing superparamagnetic manganese iron oxide nanoparticles as the key component， fibroblast inhibitor and DOTA-NHS ester as the modification，along with chelating the positron radionuclide 68Ga， we prepared the nanoprobe 68Ga-DOTA-UMFNPs-FAPI-04. Characterization of nanoprobe and analysis of its cytotoxicity， radiochemical purity and stability were performed during the whole process. The observation of the distribution of nanoprobes in normal mice was performed. The effect of nanoprobes on MRI imaging on tumor-bearing mice was analyzed. ResultsAfter purification， the radiochemical purity of probe was 94%， also it had high stability. MRI T2 test showed that its T2 relaxation rate was about 39.02 mM-1·s-1. The bio-distribution in the normal mice showed that 68Ga-DOTA-UMFNPs- FAPI-04 had a higher uptake in liver and spleen. MRI imaging demonstrated that tumor could be observed clearly after probe injection in 30 minutes. ConclusionsWe have successfully constructed the PET/MRI dual-modal imaging probe 68Ga-DOTA-UMFNPs-FAPI-04. It has the characteristics of MRI T2 contrast agent and it also performs well in the MRI imaging of prostate tumors and has the potential of PET imaging. The study provides a new idea for constructing a multi-modal imaging probe for prostate cancer.
